Study protocol for the OligoMetastatic Esophagogastric Cancer (OMEC) project: A multidisciplinary European consensus project on the definition and treatment for oligometastatic esophagogastric cancer
OMEC-working group (Supplementary File 1)
(2023) European Journal of Surgical Oncology, volume 49, issue 1, pp. 21 - 28
(Article)
Abstract
BACKGROUND: A uniform definition and treatment for oligometastatic esophagogastric cancer is currently lacking. However, a comprehensive definition of oligometastatic esophagogastric cancer is necessary to initiate studies on local treatment strategies (e.g. metastasectomy or stereotactic radiotherapy) and new systemic therapy agents in this group of patients. For this purpose, the OligoMetastatic
... read more
Esophagogastric Cancer (OMEC) project was established. The OMEC-project aims to develop a multidisciplinary European consensus statement on the definition, diagnosis, and treatment for oligometastatic esophagogastric cancer and provide a framework for prospective studies to improve outcomes of these patients. METHODS: The OMEC-project consists of five studies, including 1) a systematic review on definitions and outcomes of oligometastatic esophagogastric cancer; 2) real-life clinical scenario discussions in multidisciplinary expert teams to determine the variation in the definition and treatment strategies; 3) Delphi consensus process through a starting meeting, two Delphi questionnaire rounds, and a consensus meeting; 4) publication of a multidisciplinary European consensus statement; and 5) a prospective clinical trial in patients with oligometastatic esophagogastric cancer. DISCUSSION: The OMEC project aims to establish a multidisciplinary European consensus statement for oligometastatic esophagogastric cancer and aims to initiate a prospective clinical trial to improve outcomes for these patients. Recommendations from OMEC can be used to update the relevant guidelines on treatment for patients with (oligometastatic) esophagogastric cancer.
show less
Download/Full Text
Keywords: Esophageal cancer, Gastric cancer, Metastasectomy, Oligometastasis, Radiotherapy, Oncology, Surgery, Review, Journal Article
ISSN: 0748-7983
Publisher: W.B. Saunders Ltd
Note: Funding Information: The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Dr. Hawkins reports grants from NIHR Biomedical Research Centre at University College London Hospitals NHS Foundation Trust , outside the submitted work; Dr. Smyth reports personal fees from AMAL Therapeutics, Astellas Pharma , AstraZeneca , Beigene, Five Prime Therapeutics , Merck , Pfizer , Roche , Servier and Zymeworks and institutional funding for clinical trials research from Astra Zeneca, Astellas , Basilea, BMS, Daiichi Sankyo, Roche , Macrogenics and MSD. Dr. Moehler reports grants and non-financial support from EORTC , grants and non-financial support from AIO, grants and non-financial support from German Cancer Aid , grants and non-financial support from BMBF , during the conduct of the study; personal fees from Falk Foundation , personal fees from Lilly, grants and personal fees from MSD, personal fees from Roche, grants and personal fees from Pfizer , grants, personal fees and non-financial support from Amgen , grants, personal fees and non-financial support from Bristol-Myers Squibb , grants and personal fees from Merck Serono, personal fees from MCI Group, personal fees from Taiho, outside the submitted work; Dr. van Laarhoven reports consultant or advisory role: BMS, Dragonfly, Lilly, Merck, Nordic Pharma, Servier, outside the submitted work; research funding and/or medication supply: Bayer , BMS , Celgene , Janssen, Incyte, Lilly , Merck , Nordic Pharma , Philips , Roche , Servier , outside the submitted work; Dr. van Hillegersberg is proctor for Intuitive Surgical and consultant for Medtronic , the other authors have nothing to disclose. Publisher Copyright: © 2022 The Authors
(Peer reviewed)
